CRUCELL/US NAVY SIGN PACT TO TEST ADVAC-BASED VACCINE.Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRXL), Leiden, The Netherlands, has signed a Cooperative Research and Development Agreement “CRADA” redirects here. For other uses, see CRADA (disambiguation). A Cooperative Research and Development Agreement (CRADA) is an agreement between a government agency and a private company to work together. (CRADA) with the Naval Medical Research Center of the US Navy to construct AdVac-based vaccines against anthrax and plague and test them in non-human primates. Like Ebola and Marburg, anthrax and plague are among the so-called 'Category A' agents, which are considered by the Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), agency of the U.S. Public Health Service since 1973, with headquarters in Atlanta; it was established in 1946 as the Communicable Disease Center. (CDC See Control Data, century date change and Back Orifice. CDC - Control Data Corporation ) and the World Health Organization (WHO) to pose a significant risk in the event of use as bioterrorist agents. Category A agents can be easily disseminated or transmitted from person-to-person, result in high rates of mortality, may cause public panic and require special action for public health preparedness. Crucell is already in the course of developing an Ebola vaccine with the Vaccine Research Center (VRC) of the US National Institutes of Health and the US Army Medical Research Institute for Infectious Diseases (USAMRIID USAMRIID United States Army Medical Research Institute of Infectious Diseases (US DoD) ), utilizing adenovirus vector technology and PER.C6 production technology. The same technology will be used for the collaboration with the US Navy on anthrax and plague. Under the terms of the CRADA, Crucell has obtained an option on exclusive commercialization rights to any vaccine that could result from the collaboration. "This program builds directly on our experience with the AdVac and PER.C6 technologies utilized in the HIV programs with Merck, IAVI and Harvard, our malaria program with NIH and the US Army and the TB program with Aeras," said Crucell's chief scientific officer, Dr. Jaap Goudsmit. "The primate studies are modeled after the Ebola studies we have conducted with the VRC and USAMRIID. We are very proud that AdVac technology is gaining wider acceptance as a system for population-wide vaccination in the area of biodefense." About Crucell Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis. and rabies. The company's development programs include collaborations with: sanofi pasteur for influenza vaccines; the U.S. National Institutes of Health for Ebola and malaria vaccines; and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research This article is about the U.S. Army medical research institute (not the hospital). Otherwise, see Walter Reed (disambiguation). The Walter Reed Army Institute of Research (WRAIR) is the largest biomedical research facility administered by the U.S. and New York University New York University, mainly in New York City; coeducational; chartered 1831, opened 1832 as the Univ. of the City of New York, renamed 1896. It comprises 13 schools and colleges, maintaining 4 main centers (including the Medical Center) in the city, as well as the for a malaria vaccine. Crucell's products are based on its PER.C6 production technology. The company also licenses its PER.C6 technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, visit http://www.crucell.com or call 212/926-1733. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion